Drug Shortage Report for TARO-DOXORUBICIN LIPOSOMAL
| Report ID | 173730 |
| Drug Identification Number | 02493020 |
| Brand name | TARO-DOXORUBICIN LIPOSOMAL |
| Common or Proper name | DOXORUBICIN |
| Company Name | TARO PHARMACEUTICALS INC |
| Market Status | MARKETED |
| Active Ingredient(s) | DOXORUBICIN HYDROCHLORIDE |
| Strength(s) | 2MG |
| Dosage form(s) | SUSPENSION |
| Route of administration | INTRAVENOUS |
| Packaging size | 10ML |
| ATC code | L01DB |
| ATC description | CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2022-10-16 |
| Estimated end date | 2023-01-27 |
| Actual end date | 2023-01-13 |
| Shortage status | Resolved |
| Updated date | 2023-01-19 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 130 EAST DRIVE BRAMPTON, ONTARIO CANADA L6T 1C1 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v12 | 2023-01-19 | French | Compare |
| v11 | 2023-01-19 | English | Compare |
| v10 | 2023-01-10 | French | Compare |
| v9 | 2023-01-10 | English | Compare |
| v8 | 2022-12-12 | French | Compare |
| v7 | 2022-12-12 | English | Compare |
| v6 | 2022-11-24 | French | Compare |
| v5 | 2022-11-24 | English | Compare |
| v4 | 2022-11-15 | French | Compare |
| v3 | 2022-11-15 | English | Compare |
| v2 | 2022-11-04 | French | Compare |
| v1 | 2022-11-04 | English | Compare |
Showing 1 to 12 of 12